Description
Recombinant Human Siglec-2/CD22 Protein
| Catalog number: | B2019195 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 50 g |
| Molecular Weight or Concentration: | 75.2 kDa |
| Supplied as: | Powder |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | SIGLEC-2 Protein, Human; SIGLEC2 Protein, Human |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Shi S, Zhong H, Ma L, Nong J, Bai AB, Chen FL, Wu JM. [Optimal expression and activity detection of recombinant, chimeric and genetically engineered tetravalent anti-human CD22 antibodies in P.pastoris] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Jun;28(6):629-32.
- Wong KL, Li Z, Ma F, Wang D, Song N, Chong CH, Luk KK, Leung SO. SM03, an Anti-CD22 Antibody, Converts Cis-to-Trans Ligand Binding of CD22 against 2,6-Linked Sialic Acid Glycans and Immunomodulates Systemic Autoimmune Diseases J Immunol. 2022 Jun 15;208(12):2726-2737.
- Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia Hematology Am Soc Hematol Educ Program. 2012;2012:660-6.
- Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia Leuk Lymphoma. 2009 Oct;50 Suppl 1(Suppl 1):32-7.
- Law CL, Sidorenko SP, Chandran KA, Zhao Z, Shen SH, Fischer EH, Clark EA. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation J Exp Med. 1996 Feb 1;183(2):547-60.
- Ruella M, June CH. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You Curr Hematol Malig Rep. 2016 Oct;11(5):368-84.
- Wu CM, Roth TL, Baglaenko Y, Ferri DM, Brauer P, Zuniga-Pflucker JC, Rosbe KW, Wither JE, Marson A, Allen CDC. Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins J Immunol Methods. 2018 Jun;457:33-40.
- Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound J Exp Med. 2002 May 6;195(9):1207-13.
- La Cava A. Targeting B cells with biologics in systemic lupus erythematosus Expert Opin Biol Ther. 2010 Nov;10(11):1555-61.
